Ribon Therapeutics

Ribon Therapeutics

  • Founded: 2015
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: Solid tumors
  • Drug types: ONC, DRM
  • Lead product: RBN-2397
  • Product link: https://ribontx.com/pipeline-overview/
  • Funding: $25M Jan 2023; $65M C Jul 2021; $65M B Jan 2019; $20m Oct 2017; $10M Mar 2016
  • Investors: Novartis Venture, JJDC, Celgene, Column Group, Deerfield Management, US Venture Partners, Osage University Partners, Takeda Ventures, Euclidean Capital, Pfizer



job board

Short description:

Cancer drugs that target specific types of poly ADP-ribose polymerase

Drug notes:

RBN-3143 Clin1 atopic dermatitis; 3 undisclosed programs RD undisclosed

Long description:

Ribon Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecules targeting stress support pathways in cancer and inflammation. The company's lead product candidate, RBN-2397, is a potent, selective, and orally available small molecule inhibitor of the monoPARP, PARP7, for the treatment of solid tumors. Ribon Therapeutics is also developing RBN-3143, a PARP14 inhibitor, for the treatment of solid tumors and hematologic malignancies.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com